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Background: Establishing inflammatory activity in sarcoidosis patients with persistent disabling
symptoms is important. Whole body F18-FDG PET/CT (PET) appeared to be a sensitive method
to detect inflammatory activity in newly diagnosed symptomatic sarcoidosis. The aim was to
assess the presence of inflammatory activity using PET in sarcoidosis patients with unexplained
persistent disabling symptoms and the association between PET findings and serological inflam-
matory markers.
Methods: Sarcoidosis patients who underwent a PET between June 2005 and June 2010
(n Z 89), were retrospectively included. All PET scans were examined and positive findings
were classified as thoracic and/or extrathoracic. As serological markers of inflammatory
activity angiotensine-converting enzyme (ACE), soluble interleukin-2 receptor (sIL-2R), and
neopterine were considered.
Results: In 65/89 (73%) of the studied patients PET was positive, 52 of them (80%) had serolog-
ical signs of inflammatory activity. In 14/15 patients with a Chest X-ray stage IV PET was posi-
tive. In 80% of the PET positive patients extrathoracic inflammatory activity was found.
Sensitivity of combined serological inflammatory markers for the presence of inflammatoryt of Respiratory Medicine, Maastricht University Medical Centre (MUMC), PO Box 5800, 6202 AZ
1 43 3877043; fax: þ31 842234007.
(M. Drent).
1 Elsevier Ltd. All rights reserved.
1918 R.L.M. Mostard et al.activity as detected by PET was 80%, specificity 100%, positive predictive value 100%, negative
predictive value 65%.
Conclusions: The majority of sarcoidosis patients with persistent disabling symptoms, even
those with radiological stage IV, had PET positive findings with remarkably 80% extrathoracic
lesions. In 20% PET was positive without signs of serological inflammatory activity. PET ap-
peared to be of additional value to assess inflammatory activity in patients with persistent
symptoms in the absence of signs of serological inflammatory activity and to detect extrathor-
acic lesions.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Sarcoidosis is a multisystemic disease characterised by
activity of cellular immunity with formation of non-
caseating granuloma in various organ systems.1 Establishing
the presence of inflammatory activity is helpful in moni-
toring the course of sarcoidosis and in the follow-up of the
effect of treatment.2e4 In contrast to acute sarcoidosis,5,6
assessment of inflammatory activity in sarcoidosis
patients with persistent disabling symptoms remains
a challenge for the clinician.
The assessment of inflammatory activity by clinical and
radiographic features can be complicated by the fact that
other organs than evaluated might be involved. Symptoms
like fatigue can be nonspecific and difficult to objectify.7e9
Furthermore, symptoms like cough and dyspnoea might be
related to ongoing inflammatory activity as well as to end-
stage disease, i.e. pulmonary fibrosis. It is important to be
informed about the presence or absence of inflammatory
activity as fibrosis itself is irreversible. In general, patients
with fibrosis without ongoing inflammatory activity are
supposed not to benefit from immunosuppressive treat-
ment.7 A technique, able to evaluate the presence of
inflammatory activity per organ system, is therefore
desirable.
Inflammatory activity is characterised by ongoing T-cell
and macrophage activity and granuloma formation, reflec-
ted by an increase of serological markers of inflammatory
activity, i.e. angiotensine-converting enzyme (ACE),
soluble interleukin-2 receptor (sIL-2R) and neopterine, or
abnormality in glucose metabolism.6,10,11 The reported
sensitivity and specificity of ACE, produced in granuloma is
moderate, even if corrected for genotype (ACE).12,13 sIL-
2R, mainly secreted by activated T-cells, is elevated in
patients with active sarcoidosis.5,14,15 Neopterin represents
activation of the monocyte/macrophage system, and is
found to be increased in active disease as well.5,14,15
Although the value of these separate markers for assess-
ing disease activity has been studied, the value of
combining these serological markers is unknown.5,14e18
F18-FDG PET/CT (PET) is used for detecting high glucose
metabolism in malignancies, infectious diseases and fever
of unknown origin.10,11,19 High uptake of F18-FDG has also
been reported in patients with sarcoidosis.6,20e22 Presum-
ably inflammatory cells including activated macrophages,
lymphocytes and neutrophils are responsible for the accu-
mulation of FDG.19,23e25 To date, an increase of the number
of neutrophils in BAL-fluid was found to be associated withan unfavourable outcome.5,26 According to these findings it
is tempting to speculate that increased FDG uptake in the
pulmonary parenchyma is associated not only with inflam-
matory activity but also with disease severity.
Recently, the value of PET in assessing inflammatory
activity in newly diagnosed, symptomatic sarcoidosis
patients was shown with a high (94%) sensitivity.6 However,
the potential of PET to depict inflammatory activity in
patients with persistent disabling symptoms has to be
established. The aim of this retrospective study was to
assess the presence of inflammatory activity using PET in
sarcoidosis patients with unexplained persistent disabling
symptoms for at least one year and the association between
PET findings and serological inflammatory markers.Materials and methodsStudy population
Between June 2005 and June 2010 a PET was performed in
122/512 sarcoidosis patients referred to the interstitial lung
disease service (ild care team) of the department of
Respiratory Medicine at the Maastricht University Medical
Centre (Maastricht, The Netherlands), a tertiary referral
centre. The indication for the PET was the presence of
unexplained disease related disabling symptoms that per-
sisted for at least one year. Persistent disabling symptoms
were defined as the presence of more than one symptom
that had substantial influence on quality of life, and that
could not be explained with the results of routine investi-
gations including lung function tests or Chest X-rays (CXR).
These symptoms included fatigue (Fatigue Assessment
Scale (FAS) 22),27 symptoms compatible with small fibre
neuropathy (SFN; SFN Screenings List (SFNSL) score 11),28
arthralgia and/or muscle pain, dyspnoea (MRC dyspnoea
scale 3), exercise intolerance or cough. Laboratory
testing, lung function testing and a CXR were performed
within an interval of less than two weeks of the PET scan-
ning. Blood samples were simultaneously obtained. In the
routine workup all patients completed the FAS27 and the
SFNSL.28 Sarcoidosis was proven by the presence of non-
caseating granulomas on biopsy according with a compat-
ible clinical picture. Moreover, other causes of
granulomatous disease were excluded, according with the
consensus statement on sarcoidosis of the American
Thoracic Society (ATS)/European Respiratory Society (ERS)/
World Association of Sarcoidosis and Other Granulomatous
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tence of other diseases that are able to cause PET positive
findings. Therefore, five patients with common variable
immunodeficiency (CVID), five patients with malignancy
and one patient with both rheumatoid arthritis and
amyloidosis were excluded. After exclusion for these
criteria, 111 patients were selected. Due to an inappro-
priate interval between PET scanning and obtaining blood
samples another 22 patients were excluded. Finally, 89
patients were included. Inflammatory activity was consid-
ered to be present in case the PET demonstrated positive
findings. Relevant clinical data were gathered retrospec-
tively. All patients signed an informed consent.
Laboratory tests
Serum ACE was measured by colorimetric method (cat. no.
FU 116; Fujirebio Inc.). The imprecision of the ACE assay
was <5.6% and the reference interval 9e25 U$L1.
Serum levels of sIL-2R were analysed in commercially
available Diaclone ELISA kits (Sanquin, Amsterdam, The
Netherlands). Normal values were assessed in 40 healthy
controls mean  2SD: 240e3154 pg mL1. Serum levels of
neopterin were evaluated by the principle of a competitive
ELISA, using a kit produced by IBL (Hamburg, Germany).
Serum levels were considered elevated if >2.5 ng mL1.
Results for combined serological inflammatory marker
testing (ACE, sIL-2R and neopterin) were considered posi-
tive if at least one of the serological markers was elevated.
CRP was measured using a turbidimetric method per-
formed using the Beckman synchron CX-7 system (kit
465231; Mijdrecht, The Netherlands. The detection limit for
CRP was 2 mg mL1, with a normal range of 2e9 mg mL1.
Radiology
According to the Scadding radiographic staging system, five
stages of radiographical abnormality were recognised:
stage 0 (normal Chest X-ray (CXR)), stage I (bilateral hilar
lymphadenopathy (BHL)), stage II (BHL and parenchymal
abnormalities), stage III (parenchymal abnormalities
without BHL) and stage IV (end-stage lung fibrosis).1
Lung function tests
Forced vital capacity (FVC) was measured with a pneumo-
tachograph (Masterlab, Jaeger, Wu¨rzburg, Germany). The
diffusing capacity for carbon monoxide (DLCO) was
measured by the single-breath method (Masterlab, Jaeger,
Wu¨rzburg, Germany). Values were expressed as
a percentage of predicted values.29
F18-FDG -PET/CT
A Fluorine18-Fluorodeoxyglucose-Positron emission tomog-
raphy/Computed tomography (F18-FDG-PET/CT) scan was
performed. Patients were scanned using a Gemini PET-CT
(Philips Medical Systems) scanner with time-of-flight (TOF)
capability, together with a 64-slice Brilliance CT scanner.
This scanner has a transverse and axial Field of View (FOV)of, respectively 57.6 and 18 cm. The spatial resolution is
around 5 mm.
Patients were fasting for at least 6 h before the exami-
nation. In all patients blood glucose was measured to
ensure that the blood glucose was below 10 mmol L1. F18-
FDG (GE Health, Eindhoven, The Netherlands) was injected
intravenously and followed by physiologic saline (10 mL).
The injected total activity of FDG depended on the weight
of the patient. Mean injected dose was: 200 MBq. After
a resting period of 45 min (time needed for uptake of FDG)
PET and CT images were acquired from the head to the
feet. A low dose CT-scan was performed without intrave-
nous contrast and was used for attenuation correction of
the PET images. The PET images were acquired in 5-min bed
positions. The complete PET data set was reconstructed
iteratively with a reconstruction increment of 5 mm to
provide isotropic voxel.
All PET scans were examined independently and blindly
by two experienced nuclear physicians (MvK and SV) to
assess the inter-observer variability. Findings were scored
as either positive or negative. PET findings were described
as positive if increased FDG-uptake was seen in the medi-
astinum and/or lung parenchyma or on extrathoracic sites
like lymph nodes, visceral organs (like parotis, liver,
spleen), nasopharynx, skin, muscle, and bone. Positive
findings were classified as thoracic and/or extrathoracic.
Thoracic PET positive findings were subdivided as PET
positive findings in the pulmonary parenchyma and/or
mediastinal lymph nodes. The maximal Standard Uptake
Value (SUVmax) was measured at the various PET positive
localisations.
Statistical procedure
Statistical analyses were performed using SPSS, version
15.0 for Windows. Differences between groups in demo-
graphic characteristics and clinical characteristics (such as
duration of disease and pulmonary function tests) were
tested for statistical significance using the Student’s t-test
for independent samples in case of continuous variables or
chi-square test in case of categorical variables. A p-value of
<0.05 (two sided) was considered to indicate statistical
significance. ROC analysis was performed for assessing the
association between PET positive results and the results of
the separate serological markers. As a measure of internal
consistency and reliability to assess the inter-observer
agreement, kappa statistics were used. A k-value less
than 0.20 indicates poor, between 0.21 and 0.40 moderate,
between 0.41 and 0.60 fair, between 0.61 and 0.80 good
and between 0.81 and 1.00 excellent agreement,
respectively.Results
General clinical characteristics
Disabling symptoms of the 89 studied patients (81 Cauca-
sians, 6 Negroids and 2 Asians) included fatigue (80%; FAS
22), symptoms compatible with small fibre neuropathy
(SFN; 70%; SFNSL score 11), arthralgia and/or muscle pain
1920 R.L.M. Mostard et al.(59%), dyspnoea (45%; MRC dyspnoea scale 3), exercise
intolerance (38%) or cough (21%).
Treatment at admission (20 cases: 22.5%) consisted of
prednisone alone (median dose 15 mg daily (range
10e40 mg) in nine patients (10%), methotrexate (MTX)
alone (median dose 10 mg a week (range 7.5e12.5 mg)) in
four patients (4%), prednisone combined with MTX (all
patients 10 mg prednisone daily and median dose MTX
10 mg a week (range 10e12.5 mg)) in seven patients (8%).
PET scan results
A summary of the demographic and clinical characteristics
of the 89 studied sarcoidosis patients subdivided in PET
negative (nZ 24: 27%) and PET positive (nZ 65: 73%) cases
is shown in Table 1. Ninety-two % of these latter patients
demonstrated PET positive thoracic findings, 80% one or
more extrathoracic localisation(s), whereas 8% only extra-
thoracic localisations, respectively. The involved extra-
thoracic organs included peripheral lymph nodes (n Z 48),
bone (n Z 14), spleen (n Z 11), muscle (n Z 10) liver
(n Z 6), skin (n Z 2), and central nervous system (n Z 2),
respectively. No correlation between serologic inflamma-
tory markers and the various involved extrathoracic organs
was found. Analysis of the group with extrathoracic local-
isation compared with the group with exclusively thoracicTable 1 Summary of relevant clinical characteristics of the st
(n Z 24) and presence (n Z 65) of PET abnormalities and subdiv
PET negative patients
total PET -
population
treatment no t
Number 24 6 18
Age, yrs 49 (24e73) 44 (33e55) 50 (2
Sex (male) 15 (63%) 2 (33%) 13 (7
Time since diagnosis, yrs 4 (1e14) 1 (1e13) 7 (1e
BMI 27.7  4.9 26.7  3.9 28.0
Chest X-ray stage
0/I/II/III/IV
16/2/3/2/1 3/0/2/1/0 13/2
Thoracic PET þ 0 0 0
Mediastinal lymph nodes
PET þ
0 0 0
Pulmonary parenchyma
PET þ
0 0 0
Extrathoracic PETþ 0 0 0
FVC (% pred) 101  19 90  21 105
DLCO (% pred) 80  15 75  8 82 
ACE (9e25 U$L1) 17  4 13  3.0 18 
sIL-2R
(240e3154 pg mL1)
1599  671 1275  633 1706
Neopterin
(<2.5 ng mL1; n Z 62)
1.7  0.4 1.5  0.7 1.7 
CRP
(2e9 mg mL1; n Z 85)
4.3  4.2 4.7  4.6 4.1 
Data are presented as median with range in parentheses; mean  SD
Emission Tomography; -: negative; þ: positive; yrs: years; BMI: Bod
predicted values; DLCO: diffusion capacity for carbon monoxide;
interleukin-2 Receptor; CRP: C-reactive protein.
a p<0.001 PET þ versus PET-.
b p<0.05 PET þ versus PET-.PET positive findings showed no significant differences
regarding serological markers or other patient
characteristics.
Eight of the patients with CXR stage 0 (33%) were PET
positive of whom only four had exclusively extrathoracic
localisations and only three had serological signs of
inflammation.
Only one of the included patients with CXR stage IV
(n Z 15) was PET negative, of the PET positive patients 13
were positive in the pulmonary parenchyma and 10 extra-
thoracic. Of the PET positive patients with CXR stage IV, the
majority (85%) had serological signs of inflammation. An
example of a sarcoidosis patient with Chest X-ray stage IV and
signs of inflammatory activity on PET/CT is shown in Fig. 2.
The inter-observer agreement concerning the PET scores
is shown in Table 2.
Median SUV of the PET positive localisations was 7.0
(2.5e33.3).
Serological inflammatory markers and PET results
Mean ACE levels were calculated after exclusion of ACE
values <9U/L (nZ 9), because these values were under the
lower limit of the reference value and due to the use of
ACE-inhibitors. Neopterin values were only available in 62
patients (70%). Levels of sIL-2R and neopterin differedudied sarcoidosis patients divided according to the absence
ided in a treatment and no treatment group.
PET positive patients
reatment total PET þ
population
treatment no treatment
65 14 51
4e73) 45 (26e76) 48 (28e66) 44 (26e76)
2%) 35 (54%) 9 (64%) 26 (51%)
14) 2 (1e27) 3 (1e19) 1 (1e27)
 5.2 28.1  5.6 28.0  3.8 28.5  6.1
/1/1/1 8/17/24/2/14 1/3/3/0/7 7/14/21/2/7
60 (92%) 14 (100%) 46 (90%)
54 (83%) 12 (86%) 42 (82%)
43 (66%) 10 (71%) 33 (65%)
52/65 (80.0%) 10 (71%) 42 (82%)
 18 91  26 74  20 96  25
16 71  19 58  19 76  17
4 21  6 21  5 21  7
 666 4526  2577a 4340  2438a 4577  2634a
0.3 3.2  1.6a 2.8  1.0a 3.3  1.7a
4.2 11.9  16.1b 9.6  11.2 12.5  17.3
; absolute numbers or percentages if appropriate. PET: Positron
y Mass Index; FVC: forced vital capacity; % pred: percentage of
ACE: serum angiotensine converting enzyme; sIL-2R: soluble
Table 2 Inter-observer agreement concerning PET scores.
Weighted kappa
PET positivity 1.000
Thoracic PET positivity 0.975
Mediastinal lymph nodes PET positivity 0.931
Pulmonary parenchyma PET positivity 0.912
Extrathoracic PET positivity 1.000
PET: Positron Emission Tomography.
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group (p < 0.001; Table 1). In the PET negative group, in
none of the patients serological signs of inflammation were
found, whereas in the PET positive group 13 patients (20%)
had no serological signs of inflammation (Table 3).
ROC analysis results for the association between PET
positive results and the results of the separate serological
markers are presented in Fig. 1. Overall, the area under the
curve (AUC) of sIL-2R and neopterin is significantly different
from the null-hypothesis, true area Z 0.5 (meaning no
discrimination). Sensitivity and specificity of both the
separate and the combined results of the serologicalTable 3 The association between PET results and sero-
logical inflammatory activity markers.
Marker PET - PET þ
serum angiotensine
converting enzyme
(ACE) number
24 65
ACE e (n Z 75) 100% (n Z 24) 78% (n Z 51)
ACE þ (n Z 14) 0% (n Z 0) 22% (n Z 14)
soluble interleukin-2
receptor (sIL-2R)
number 24 65
sIL-2R e (n Z 45) 100% (n Z 24) 32% (n Z 21)
sIL-2R þ (n Z 44) 0% (n Z 0) 68% (n Z 44)
neopterin
number 20 42
neopterin e (n Z 35) 100% (n Z 20) 36% (n Z 15)
neopterin þ (n Z 27) 0% (n Z 0) 64% (n Z 27)
Combined serological
inflammatory
markers (CIM)
number 24 65
CIM e (n Z 37) 100% (n Z 24) 20% (n Z 13)
CIM þ (n Z 52) 0% (n Z 0) 80% (n Z 52)
C-reactive protein
(CRP)
number 23 62
CRP e (n Z 61) 83% (n Z 19) 68% (n Z 42)
CRP þ (n Z 24) 17% (n Z 4) 32% (n Z 20)
PET: Positron Emission Tomography; -: negative; þ: positive;
Combined serological inflammatory markers: defined as positive
if at least one serological marker (ACE, sIL-2R or neopterin) was
elevated.
Fig. 1 ROC curve of the association between PET positive
results and serological inflammatory activity marker
separately.inflammatory markers for detecting inflammatory activity
as shown by PET is demonstrated in Table 3. The sensitivity
of combined results of the serological markers was 80%.
Specificity was 100% for all serological markers. Positive
predictive value (PPV) was 100% in all cases. Negative
predictive value of combined results of the serological
markers was 65%. As shown in Table 3, adding CRP to the
serological inflammatory classification would increase the
sensitivity, but decrease the excellent specificity and PPV
of the combined serological markers.
Analysis of the relation between levels of the studied
serological markers and the Chest X-ray (CXR) stages in the
patients with PET positive findings in the pulmonary
parenchyma showed no significant differences. In the group
with PET positive findings in the pulmonary parenchyma,
TLCO and FVC were significantly lower in the patients with
CXR stage IV compared with the other CXR stages.
Comparison of clinical or laboratory parameters between
PET positive CXR stage IV patients (n Z 14) and PET
negative CXR stage IV patients (nZ 1) was not possible due
to the low number in the latter group.
Discussion
This study demonstrated that the majority of sarcoidosis
patients with unexplained persistent disabling symptoms
had signs of inflammatory activity detected by PET positive
findings. PET positive findings were associated with
increased levels of serological inflammatory parameters in
sarcoidosis, especially with sIL-2R and neopterin levels.
Fig. 2 Example of a sarcoidosis patient with Chest X-ray stage IV and signs of inflammatory activity on PET/CT. (a) Chest X-ray
showing bilateral irregular opacities and some surrounding lung deformation. (b) CT-scan image at thoracic level showing bilateral
perihilar opacities, bilateral hilar and mediastinal lymphadenopathy with calcifications and deformation of the surrounding lung
architecture. (c) PET/CT fusion image at thoracic level showing diffuse increased FDG-uptake in the bilateral perihilar opacities.
(d) PET image at thoracic level showing diffuse bilateral increased FDG-uptake in the pulmonary parenchyma.
1922 R.L.M. Mostard et al.Positive predictive value of serological inflammatory
marker testing for the presence of inflammatory activity on
PET was excellent (100% in this study). However, negative
predictive value of serological inflammatory marker
testing, even if the results were combined, was moderate.
Assessing inflammatory activity in sarcoidosis patients
without lung functional or radiological deterioration but
with unexplained persistent disabling symptoms often is
problematic. In this study, the value of PET for assessment
of inflammation in this difficult category of patients is
demonstrated since almost 75% of the patients with
persistent disease related symptoms had signs of inflam-
matory activity as detected by PET. Although the study
design and population was not completely comparable this
was in line with the results of Teirstein et al.20 It is
important to stress that either normal CXR findings (stage 0)
or CXR stage IV (and thus signs of fibrosis) do not exclude
inflammatory activity in the pulmonary parenchyma. The
latter still harbours significant inflammatory lesions that
might be target, together with respiratory functional
impairment, for appropriate treatment. Because of the
radiation dose and expense of performing PET, measure-
ment of serological inflammatory markers should be, after
excluding lung functional or radiological deterioration, first
performed for assessing inflammatory activity in sarcoidosis
patients with unexplained persistent disabling symptoms.
Using the strategy of combining serological marker testing
provided enough information to determine the presence of
inflammatory activity in 58% of the studied patients (52/
89). However, since the negative predictive value of sero-
logical marker testing is moderate (65%), negative sero-
logical test results do not exclude the presence of
inflammatory activity and therefore the surplus value of
PET for assessment of inflammatory activity is situated inthe group of symptomatic sarcoidosis patients without
serological signs of inflammatory activity.
In contrast with Grutters et al., no association between
sIL-2R levels and extrathoracic localisations was found in
our population.15 A possible explanation would be that the
prevalence of extrathoracic localisations in our study was
higher, which could be due to a better sensitivity of PET for
detecting extrathoracic localisation than the sensitivity of
the used diagnostic techniques (no use of PET or Gallium
scanning) in the latter study to detect extrathoracic
localisation. The prevalence of extrathoracic localisation in
the PET positive patients in our study is comparable to the
prevalence found in other studies using PET in active
sarcoidosis.6,22 Although determination of the frequency of
extrathoracic sarcoidosis localisations was not the aim of
this study, the established high frequency of these findings
shows that this is another merit of performing PET
(assessing extent of the disease).
The disabling symptoms in the 24 PET negative patients
can be caused by multiple factors.9,30,31 Sleeping disorders
may interact with fatigue in sarcoidosis.32 Twenty four of
the studied patients were evaluated for the presence or
absence of OSAS. Five of these latter patients appeared to
have an OSAS. However, these patients also suffered from
other disabling symptoms despite adequate treatment for
their OSAS. PET appeared to be positive in all these
patients, showing that inflammatory activity was still
present (data not shown).
In the Sarcoidosis Investigators study, results of the post
hoc analysis suggested a greater benefit of infliximab
therapy in patients with more severe disease.33 This indi-
cates the importance of establishing inflammatory activity
in patients with CXR stage IV disease since it may have
therapeutic implications and thus this underlines the value
Inflammatory activity on F18 FDG-PET/CT in sarcoidosis 1923of PET especially in this group of chronic sarcoidosis
patients. However, the exact value of the presence of
inflammatory activity for treatment decisions needs to be
established in future studies. A study in a small cohort of
sarcoidosis patients treated with infliximab showed that
changes in PET-imaging correlated with clinical signs of
improvement to a considerable extent.4 Apart from the
value of PET-imaging in treatment decisions or follow-up,
simply validating that there is an organic cause for the
symptoms can be extremely reassuring to many patients.34
Since this was a retrospective study and bronchoalveolar
lavage (BAL) was infrequently performed close to the date
of the PET, we only have gathered data on BAL fluid analysis
of 20 PET-positive patients of whom 6 appeared to have
stage IV disease on chest X-ray. All 20 cases showed signs of
inflammation in the BAL (increased number of lymphocytes
as well as polymorphonuclear neutrophils, indicating
disease severity).5,26 These signs were even more prom-
inent in the 6 cases with chest X-ray stage IV (data not
shown). This is in line with Keijsers R et al. who found that
increased FDG uptake in the pulmonary parenchyma
correlated with the number of neutrophils in BAL-fluid of
sarcoidosis patients.23
Several attempts to define disease activity in sarcoidosis
have been undertaken. However, no single marker available
can accurately predict the likelihood of activity or
progression.3,16 Comparing PET results with pulmonary
function and CXR only addresses pulmonary involvement
and does not provide any information about the presence or
absence of systemic inflammatory activity. Since PET can
be considered as a useful additional tool in the evaluation
of systemic sarcoidosis, comparison with the already
existing markers of systemic inflammatory activity is
needed. Although we are aware of the limitations of sero-
logical markers, these were in the present clinical study the
most appropriate.
Our centre is a referral centre for sarcoidosis, and,
therefore the refractory character may be more severe
than in a general sarcoidosis population. Moreover, PET was
not performed in every referred patient. This might cause
a selection bias. However, a PET scan was really not
necessary in every patient. The questions and reasons for
referring the patients to our interstitial lung disease service
were very divers. It varied from a therapeutic advice in
refractory sarcoidosis like hypercalcaemia, uveitis or
severe respiratory impairment not responding to cortico-
steroids to questions about genetic issues or occupational
exposures. In these patients a PET was not indicated to
answer the questions appropriately. That does not mean
the patients had less severe sarcoidosis, however. The
subpopulation that did not have a PET scan did not differ
from the population who underwent a PET regarding clinical
data (data not shown). Although no other diseases that are
able to cause PET positive findings were diagnosed during
the follow-up, other causes of PET positive findings cannot
be excluded completely.
In conclusion, in the absence of serological signs of
inflammation, PET appeared to be of additional value to
assess inflammatory activity in sarcoidosis patients with
unexplained persistent disabling symptoms. In almost 75% of
these sarcoidosis patients PETwas positive,with the presence
of extrathoracic lesions in 80% of them. Remarkably, themajority of patientswith radiological stage IV disease had PET
positive findings. Combining results of serological inflamma-
tory markers increased sensitivity for detecting inflammatory
activity in sarcoidosis without false positive results. Future
studies are needed to evaluate the additional value of PET in
the follow-up and management of the disease.Conflicts of interests
No conflicts of interests.References
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